- Home
- QNRX vs APVO Comparison
QNRX vs APVO Comparison
Compare QNRX & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- APVO
- Stock Information
- Founded
- QNRX 2018
- APVO 2016
- Country
- QNRX United States
- APVO United States
- Employees
- QNRX 3
- APVO N/A
- Industry
- QNRX Medical/Dental Instruments
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- APVO Health Care
- Exchange
- QNRX Nasdaq
- APVO Nasdaq
- Market Cap
- QNRX 4.8M
- APVO 4.9M
- IPO Year
- QNRX N/A
- APVO N/A
- Fundamental
- Price
- QNRX $8.59
- APVO $1.41
- Analyst Decision
- QNRX
- APVO Strong Buy
- Analyst Count
- QNRX 0
- APVO 1
- Target Price
- QNRX N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- QNRX 107.3K
- APVO 6.1M
- Earning Date
- QNRX 11-06-2025
- APVO 11-06-2025
- Dividend Yield
- QNRX N/A
- APVO N/A
- EPS Growth
- QNRX N/A
- APVO N/A
- EPS
- QNRX N/A
- APVO N/A
- Revenue
- QNRX N/A
- APVO N/A
- Revenue This Year
- QNRX N/A
- APVO N/A
- Revenue Next Year
- QNRX N/A
- APVO N/A
- P/E Ratio
- QNRX N/A
- APVO N/A
- Revenue Growth
- QNRX N/A
- APVO N/A
- 52 Week Low
- QNRX $5.01
- APVO $1.32
- 52 Week High
- QNRX $54.95
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- QNRX 70.88
- APVO 27.81
- Support Level
- QNRX $7.35
- APVO $1.40
- Resistance Level
- QNRX $7.79
- APVO $2.71
- Average True Range (ATR)
- QNRX 0.38
- APVO 0.21
- MACD
- QNRX 0.13
- APVO 0.03
- Stochastic Oscillator
- QNRX 46.79
- APVO 6.47
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.